<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894645</url>
  </required_header>
  <id_info>
    <org_study_id>Ma-Spore ALL 2010</org_study_id>
    <nct_id>NCT02894645</nct_id>
  </id_info>
  <brief_title>Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study</brief_title>
  <official_title>Ma-Spore ALL 2010 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to continue to improve the cure rate of childhood
      acute lymphoblastic leukemia (ALL) in Singapore and Malaysia in the context of a multi-centre
      cooperative trial using a risk-stratified therapy based primarily on early response to
      therapy utilizing a simplified minimal residual disease (MRD-lite) platform.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed on the premise that a risk classification strategy combining clinical
      and genetic presenting features with molecular assessment of MRD should reduce both
      treatment-related toxicities and relapse risk.

      The patient will be assigned to one of the 3 risk groups depending on his/her response to the
      treatment and special laboratory tests. There are no experimental drugs in this study. All
      the drugs used are standard established treatment for childhood ALL for the last 30 years.
      The difference in treatment is by changes in the frequency and dose of the chemotherapy
      drugs.

      The overall study treatment lasts for about 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>EFS was estimated from time of diagnosis to time of first event or of patient's last follow-up. Failure to achieve complete remission (CR), relapse, death in continuous remission from whatever cause, secondary leukemia and abandonment (absence from scheduled therapy for more than 6 weeks) were considered as events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS was determined from diagnosis to time of death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease (MRD) measurement</measure>
    <time_frame>At time point of Day 33, week 8 and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with chemotherapy-related adverse events as assessed by CTCAE version 4.0</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity of chemotherapy during various phases of therapy</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk (HR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Oral</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Asparaginase</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Intrathecal/ Intravenous/ Oral</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Intravenous/ Subcutaneous injection</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>Oral</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Oral</description>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_label>Intermediate Risk (IR)</arm_group_label>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Oral (For BCR-ABL ALL only)</description>
    <arm_group_label>High risk (HR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of non-Burkitt B-lineage ALL

          2. 1 to 17 years of age (before 18th birthday)

          3. Renal function within normal range for age

          4. Liver function within normal range for age

          5. Able to participate in the full 2 years of treatment

        Exclusion Criteria:

          1. Age less than one year or age greater than/equals to 18 years

          2. Previous treatment with cytotoxic agents or high-dose steroids

          3. Mixed phenotype acute leukemia (MPAL)

          4. ALL as secondary malignancy

          5. Abnormal renal or liver function

          6. Doubtful compliance or unable to afford full course of therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Yeoh, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ma-spore Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allen Yeoh, MBBS</last_name>
    <phone>(+65) 6772 4406</phone>
    <email>allen_yeoh@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany Arrifin, MBBS</last_name>
      <phone>+603 7949 6785</phone>
      <email>hany@ummc.edu.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Subang Jaya Medical Centre</name>
      <address>
        <city>Subang Jaya</city>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai Peng Lin, MBBS</last_name>
      <email>flslhp@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lee Lee Chan, MBBS</last_name>
      <email>drchanleelee@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Yeoh, MBBS</last_name>
      <phone>(+65) 6772 4406</phone>
      <email>allen_yeoh@nuhs.edu.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ah Moy Tan, MBBS</last_name>
      <phone>(+65) 63941039</phone>
      <email>tan.ah.moy01@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

